Leaderna Biostructures Spółka z Ograniczoną Odpowiedzialnością (KRS 0000831209, NIP 7010972599) is a Polish company, headquartered in Gdańsk, Pomorskie voivodeship. LEADERNA BIOSTRUCTURES operates in: Manufacture of pharmaceutical preparations (PKD 21.20.Z). Industry: Pharmaceuticals. The company has been listed in the National Court Register since February 26, 2020. LEADERNA BIOSTRUCTURES's most recently reported net revenue was 200 PLN for 2024.
Negative equity
Negative equity in 3 of 5 available reporting years.
No arrears identified in the analyzed sources
No arrears or bankruptcy proceedings identified in the analyzed sources.
Business profile - Leaderna Biostructures
Identity
- Name
- Leaderna Biostructures Spółka z Ograniczoną Odpowiedzialnością
- Legal form
- SPÓŁKA Z OGRANICZONĄ ODPOWIEDZIALNOŚCIĄ
- Founded
- February 26, 2020
- Registry status as of
- June 22, 2026
- Latest entry
- June 22, 2026
- Founding act
- 12.02.2020 R., NOTARIUSZ MICHAŁ LORENC, KANCELARIA NOTARIALNA W WARSZAWIE, REP.A NR 768/2020.
Articles of association history (2)
- February 12, 2020: 12.02.2020 R., NOTARIUSZ MICHAŁ LORENC, KANCELARIA NOTARIALNA W WARSZAWIE, REP.A NR 768/2020.
- June 25, 2025: 25.06.2025 R.; REP. A NR 5184/2025; NOTARIUSZ KAROL ALEKSANDROWICZ; KANCELARIA NOTARIALNA W GDAŃSK UL. JAŚKOWA DOLINA 132/16; ZMIANA § 3, § 6 UST. 1 UMOWY SPÓŁKI, PRZYJĘCIE TEKSTU JEDNOLITEGO UMOWY SPÓŁKI.
Activities
Main activity
21.20.ZManufacture of pharmaceutical preparations
Other activities
General codes (divisions and groups)
General codes indicate a PKD division or group without a specific subclass.
Address and contact
- Address
- UL. TARG RYBNY, 11, 2, 80-838, GDAŃSK, POLSKA
- Voivodeship
- POMORSKIE
- District
- GDAŃSK
- Not disclosed in the registry
- Website
- Not disclosed in the registry
- E-delivery address
- AE:PL-69605-37817-CBFBA-24
Risk and payment profile - Leaderna Biostructures
Credibility rating
1 / 100
Very poor credibility
Insolvency risk
Very high
Significant formal threat
Closure risk
40
/ 100
Risk comparison - scale 0 (safe) → 100 (critical)
Organizational stability signals
No instability signals - ownership, management, PKD codes and company name remain relatively stable.
Shareholder changes
1
1/6 yrs
Board changes
1
1/6 yrs
PKD changes
1
1/6 yrs
Name changes
0
0/6 yrs
Data from 6 years of registry activity.
Credibility history
Payment reliability score from 2020–2024
Current: E (1/100)
Trend: deteriorating (-8.2 pts/year)
Bardzo słaba wiarygodność płatnicza – współpraca handlowa wiąże się z wysokim ryzykiem braku zapłaty.
Trade credit limit history
Standard limit from 2020–2024
Current: 2.38 PLN
Safe: 0.24 PLN
Difference between risk models
Closure - probability of ceasing operations (operational continuity). Insolvency - probability of formal bankruptcy / restructuring. The models use different data - results can diverge significantly when balance-sheet data is incomplete.
Operational status - Leaderna Biostructures
Founded
February 26, 2020
6 years in operation
Legal form
SPÓŁKA Z OGRANICZONĄ ODPOWIEDZIALNOŚCIĄ
Registry: RejP
Headquarters
GDAŃSK
POMORSKIE
Primary PKD
21.20.Z
Manufacture of pharmaceutical preparations
Share capital
10.0 K PLN
200 shares total
Shareholders
2
shareholders
Board
2 people
Filed years
5 years
2020–2024 · profitable: 2/5
Registry entries
21
latest: June 22, 2026
Risk signals
Revenue
200 PLN
2024
Net profit
-89.3 K PLN
2024
Assets
24.4 K PLN
2024
Equity
-118.9 K PLN
2024
EBITDA
-86.0 K PLN
2024
Companies in the same location
Public procurement
Trademarks
Reviews
Rate business credibility - Leaderna Biostructures.
No ratings
Related articles
News
Bioton 2025: record EBITDA of PLN 53.8 m and revenue of PLN 235.9 m, but still a PLN 16.4 m net loss
Warsaw-based Bioton S.A. (KRS 0000214072) - the only Polish manufacturer of biosynthetic human insulin - closed 2025 with revenue of PLN 235.9 m and EBITDA of PLN 53.82 m (margin 18.72%), but a net loss of around PLN -16.4 m keeps the company in the red. EBITDA improved 76% versus 2024 (PLN 30.6 m), driven by international expansion (Malaysia ~PLN 100 m a year) and a contract to produce the insulin analogue Glargine. Yifan Pharmaceutical controls 31.65% of capital indirectly.
News
Celon Pharma 2025: record PLN 244 m revenue, but net loss deepens to PLN 79.4 m - the 2026 outlook hinges on Salmex registration in China and the GLP-1 programme
Celon Pharma S.A. (KRS 0000437778, Kiełpin/Łomianki) closed 2025 with consolidated revenue of PLN 244.34 m (+17.9% YoY), EBITDA of PLN 21.42 m (+42%) and a deepened net loss of PLN -79.36 m (vs PLN -34.45 m a year earlier). The deeper loss reflects spending on the innovative GLP-1 segment. The generics segment grows (+15.3%) and represents 84.4% of revenue. Salmex registration in China is expected by end-2026. Maciej Wieczorek controls 58.8% of capital and 68.2% of voting rights through Glatton sp. z o.o.
